Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/05/24
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 05/29/25
End: 04/02/29
Due: 04/02/30
Phase: N/A
Priority: Normal
Start: 03/01/19
End: 01/27/25
Due: 01/27/26
Phase: N/A
Priority: Normal
Start: 02/15/23
End: 07/25/24
Due: 07/25/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | NCT06393738 | Arvinas Inc. | user2@example.com | None | 2024-09-05 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | NCT07023731 | Arvinas Inc. | user2@example.com | None | 2025-05-29 | 2029-04-02 | 2030-04-02 | - | - | 2025-07-14 |
| Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer | NCT03888612 | Arvinas Inc. | user2@example.com | None | 2019-03-01 | 2025-01-27 | 2026-01-27 | - | - | 2025-07-14 |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | NCT05549505 | Arvinas Inc. | user2@example.com | None | 2023-02-15 | 2024-07-25 | 2025-07-25 | - | - | 2025-07-14 |